PITTSBURGH, PA – November 22, 2010 –– invivodata inc.®, the industry leader in patient reported outcomes (PRO) solutions and services for global clinical research, along with its scientific and regulatory consulting division, PRO Consulting®, today opened registration for PROficiency™ 2011, its annual Patient Reported Outcomes Conference. The conference, which has become the premier event for biopharmaceutical and medical device developers using PRO data in their clinical development programs, will take place in Fort Lauderdale, Fl from April 12-14, 2011.
“PROficiency 2011 is an opportunity for clinical researchers to advance their knowledge on the what, how, and when of successfully incorporating PROs into product development and commercialization,” said Dr. Jean Paty, invivodata Co-founder and PRO Consulting Chief Scientist and Regulatory Advisor. “We’re very excited about this year’s conference – the agenda has been designed with input from international clinical researchers, and includes focused, specific sessions that aim to give attendees practical, usable takeaways.”
Now in its 4th year, PROficiency 2011 presents an opportunity for researchers to network with leading PRO experts and hear case studies and best practices from international professionals with real-world PRO experience in all stages of clinical development. This year’s conference will feature the following sessions and presenters:
- “Current Regulatory Trends in PRO Research”; John H. Powers, MD FACP FIDSA; Assistant Clinical Professor of Medicine, George Washington University School of Medicine, University of Maryland School of Medicine.
- “A Historical Operational Perspective of ePRO”; Joanne Zuck, M.P.H., Epidemiology; Project Manager, Biometrics and Data Management, Boehringer-Ingelheim Pharmaceuticals, Inc.
- “The Strategic Role of PRO"; Heather Falvey, Health Economics & Outcomes Research Director, Cardiovascular-Metabolism; Novartis Pharma, AG (invited)
- “Perspectives of ePRO from the Investigative Site"; Sean Stanton, Owner, Compass Research, LLC.
invivodata is offering 30% off registration fees for attendees who register before February 5, 2011. For additional information and to register for PROficiency 2011, visit www.invivodata.com/PROficiency2011.
About invivodata
invivodata is the only fully-integrated PRO Solutions Organization (PSO) delivering regulatory-proven strategic consulting and practical ePRO solutions to biopharmaceutical companies where patient-centered research is a priority. From consulting on scale selection and study design to direct data collection from patients using invivodata’s ePRO solutions, and then assisting in regulatory filings and meetings, invivodata helps its customers strategically use patient reported data to support labeling claims and other clinical program objectives. And through partnerships with leading CROs and eClinical technology providers, invivodata seamlessly integrates into the clinical trial ecosystem, effectively contributing to the harmonization of each function to minimize scientific and clinical risk while maximizing efficiencies. invivodata’s solutions have been used in over 300 clinical programs and is the industry-leading ePRO system in delivering primary efficacy data for global drug approvals. invivodata inc. is a privately held company with global headquarters in Pittsburgh, Pa., USA; its European headquarters is in London, England; and its technology development center is in Scotts Valley, Calif., USA. For more information, visit www.invivodata.com.
About PRO Consulting
PRO Consulting, a division of invivodata, inc., provides consulting services to help clinical research teams effectively develop, execute, and document patient reported outcome (PRO) strategies to support their clinical research objectives. The PRO Consulting team has worked on over 150 clinical studies in 50+ indications and has more than 265 years of cumulative experience in psychometrics, PRO study design, and migrating and validating electronic solutions to collect PRO data, and has extensive experience working with the FDA and other regulatory bodies. For more information please visit http://www.patientreported.com.
